Representative LC/UV chromatogram under typical analytical conditions (C18 column; mobile phase: 5–100% ACN / H2O (0.05% H3PO4), linear gradient 20 min; flow rate: 0.2 mL/min; detection: 210 nm).
NMR Spectral Data
Representative 1H NMR (500 MHz) spectrum confirming the structure of 1233B. Representative 13C NMR (125 MHz) spectrum supporting structural assignment of 1233B.
Source Organism
Scopulariopsis sp.
Summary
1233B is an opened-lactone derivative of hymeglusin that modulates HMG-CoA synthase activity in the mevalonate pathway and is used in lipid metabolism research.
Details
Hymeglusin is a fungal polyketide containing a β-lactone ring with defined stereochemistry and acts as a potent inhibitor of 3-hydroxy-3-methylglutaryl-CoA synthase. Mechanistic studies using radiolabeled hymeglusin demonstrated covalent binding to the catalytic Cys129 residue of cytosolic HMG-CoA synthase, resulting in complete inhibition of enzymatic activity. Alkylating agents such as iodoacetamide and N-ethylmaleimide block hymeglusin binding, confirming thiol reactivity as the underlying mechanism of inhibition. Biosynthetic investigations revealed that hymeglusin is assembled by a highly reducing polyketide synthase (HR-PKS), and that the ketosynthase domain catalyzes β-lactonization during chain termination. The β-lactone moiety is essential for biological activity. Because HMG-CoA synthase catalyzes a key condensation step in the mevalonate pathway upstream of HMG-CoA reductase, hymeglusin and related derivatives such as 1233B provide mechanistically distinct tools for studying cholesterol biosynthesis, isoprenoid formation, and antimicrobial resistance modulation, including potential combination strategies against MRSA.